Company Performance Metrics
- Jean-Christophe Marcoux: Chief Strategy Officer
- Nathalie Huitorel: Chief Financial Officer
GENFIT is a late-stage biopharmaceutical company dedicated to the discovery and development of innovative therapeutic and diagnostic solutions in metabolic and liver related diseases where there are considerable unmet medical needs, corresponding to a lack of approved treatments.
Their pioneering research is based on a strong heritage, stemming
from in-house knowledge and their desire to strive for excellence. Their drug discovery efforts are based on selecting specific nuclear receptors as targets and utilizing rational drug design to optimize their drug candidates.
This strong skill base associated to their scientific and clinical expertise, translational disease-driven approach and strong bioinformatics capabilities, have allowed us to build a solid scientific platform enabling us to discover and develop their drug candidates and diagnostic tools. Professor Bart Staels, a world-renowned expert in nuclear receptors, co-founded GENFIT and has played a key role in shaping their company’s expertise over the years. Today, he sits as chair of the Scientific Advisory Board, lending decades of experience and essential know-how, supporting their role as an innovative leader in the discovery of solutions for the metabolic field.
